Renovion Concludes Patient Recruitment in the P-II (CLIMB) Trial of ARINA-1 for Bronchiectasis
Shots:
- The company has completed the adult patient recruitment in the P-II (CLIMB) trial aimed at assessing the safety, tolerability and efficacy of ARINA-1 for the treatment of non-CF bronchiectasis across 10 sites in the US
- The efficacy endpoints of the study focus on the quality of life, sputum rheological markers, blood inflammatory markers and other exploratory clinical markers
- ARINA-1 is a novel nebulized therapy that functions by removing mucus and minimizing inflammation-induced damage in the airways, thereby restoring lung health
Ref: Businesswire | Image: Renovion
Related News:- Zambon’s CMS I-neb Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Non-Cystic Fibrosis Bronchiectasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
